MX2022001520A - Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos. - Google Patents

Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos.

Info

Publication number
MX2022001520A
MX2022001520A MX2022001520A MX2022001520A MX2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A
Authority
MX
Mexico
Prior art keywords
hexadienoates
opioid
hexadienoate
modification
compositions
Prior art date
Application number
MX2022001520A
Other languages
English (en)
Inventor
Georgiy Nikonov
Levon Isakulyan
Michael V Voronkov
Original Assignee
Kappa Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/540,058 external-priority patent/US11186585B2/en
Application filed by Kappa Pharma Llc filed Critical Kappa Pharma Llc
Publication of MX2022001520A publication Critical patent/MX2022001520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Abstract

La presente invención se refiere a composiciones derivadas de opiáceos y sus antagonistas útiles en áreas terapéuticas asociadas con modulación de receptores de opiáceos. Se formula una modificación de 3-hexadienoato de los opiáceos para mejorar la activación de los opiáceos con los receptores de opiáceos cuando se da por vía oral. Una modificación de 3-hexadienoato de nalbufina o una sal farmacéuticamente aceptable de la misma para mejorar la calidad de gestión de dolor cuando se da por vía intravenosa, intranasal, transdérmica, sublingual, rectal, tópica, intramuscular, subcutánea o por inhalación. Se formula una modificación de 3-hexadienoato de los antagonistas de opioides para mejorar la inhibición de los receptores de opioides cuando se dan por vía oral. Una modificación de 3-hexadienoato de naloxona o una sal farmacéuticamente aceptable de la misma para mejorar la calidad de sobriedad cuando se da por vía intravenosa, intranasal, transdérmica, sublingual, rectal, tópica, intramuscular, subcutánea o por inhalación.
MX2022001520A 2019-08-11 2020-03-07 Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos. MX2022001520A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885311P 2019-08-11 2019-08-11
US16/540,058 US11186585B2 (en) 2018-08-17 2019-08-14 Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates
PCT/US2020/021599 WO2021029914A1 (en) 2019-08-11 2020-03-07 Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates

Publications (1)

Publication Number Publication Date
MX2022001520A true MX2022001520A (es) 2022-07-21

Family

ID=74571142

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001520A MX2022001520A (es) 2019-08-11 2020-03-07 Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos.

Country Status (6)

Country Link
EP (1) EP4010078A4 (es)
JP (1) JP2022544564A (es)
CN (1) CN114828961B (es)
CA (1) CA3149152A1 (es)
MX (1) MX2022001520A (es)
WO (1) WO2021029914A1 (es)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
EP0615756B1 (en) * 1993-03-15 2001-06-27 National Science Council Nalbuphine esters and long-acting pharmaceutical compositions containing them
CN1050130C (zh) 1997-07-04 2000-03-08 卢正堂 纳洛酮酸脂和纳屈酮酸脂及系列物和制备方法
EP1149836B1 (en) 2000-04-27 2003-02-26 Oliver Yoa-Pu Hu Polynalbuphine derivatives
TWI226239B (en) 2000-05-15 2005-01-11 You-Pu Hu Novel oral pharmaceutical composition containing nalbuphine ester prodrug
MXPA03000821A (es) 2000-07-27 2004-03-18 Univ Rutgers Poliesteres y poliamidas terapeuticos.
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
US8163701B2 (en) 2005-08-19 2012-04-24 Signature Therapeutics, Inc. Prodrugs of active agents
WO2009092071A2 (en) 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
BRPI1015108A2 (pt) 2009-04-02 2016-04-26 Shire Llc pró-fármacos de aminoácidos e peptídios ligados a ácido dicarboxílico de opiáceos e seus usos
RU2012105460A (ru) 2009-07-17 2013-08-27 ШАЙЕ ЭлЭлСи Новые карбаматные и пептидные пролекарства опиоидов и их использование
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
CA2795156C (en) * 2010-04-02 2019-05-14 Alltranz Inc. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
US10449190B2 (en) * 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US10017519B2 (en) * 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US9974858B2 (en) * 2015-08-29 2018-05-22 Medrx Co., Ltd Percutaneous absorption composition
US11186585B2 (en) * 2018-08-17 2021-11-30 Kappa-Pharma LLC Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates

Also Published As

Publication number Publication date
JP2022544564A (ja) 2022-10-19
CN114828961A (zh) 2022-07-29
CA3149152A1 (en) 2021-02-18
EP4010078A4 (en) 2023-08-09
CN114828961B (zh) 2024-03-29
WO2021029914A1 (en) 2021-02-18
EP4010078A1 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
WO2004054511A3 (en) Analgesic combination comprising nalbuphine
MX2009011958A (es) Compuestos de morfina.
MX361542B (es) Compuestos de morfinan.
MX2009010378A (es) Metodos para tratar o prevenir el vomito utilizando secretagogos de hormona de crecimiento.
DK1554282T3 (da) Morphinanderivater substitueret i position 14 og deres kvaternære ammoniumsalte, fremstillingsmetode og anvendelse
MXPA05003104A (es) Hidromorfonas n-sustituidas y uso de las mismas.
IL164787A0 (en) Tachykinin receptor antagonists
HK1072940A1 (en) 8-hydroxy quinoline derivatives
UA89192C2 (ru) Производные пиролопиримидина и пиролопиридина, замещенные циклической аминогруппой, как антагонисты crf
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
WO2006020930A3 (en) Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
PL1828177T3 (pl) Nowi antagoniści receptora MCH
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
NZ590952A (en) Use of opioid antagonists for treating urinary retention
WO2007146758A3 (en) Novel mch receptor antagonists
EA030609B8 (ru) Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
MX2022001520A (es) Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos.
MX2012011216A (es) Antagonista del receptor opioide para usarse en el tratamiento de la enfermedad herpes zóster.
WO2005040157A3 (en) Novel mch receptor antagonists
SI1861360T1 (sl) Derivati pirolidina kot antagonisti histaminskega h3 receptorja
EP1988075A4 (en) PYRROLE DERIVATIVE OR SALT THEREOF
TW200700067A (en) Substituted aryl 1,4-pyrazine derivatives
MXPA05012082A (es) Compuestos como antagonistas del receptor crf1.
WO2001046198A3 (en) Nonpeptide kappa opioid receptor antagonists
MX341177B (es) Compuestos de morfina.